A new treatment for actinic keratoses, ingenol mebutate, was recently approved by the US Food and Drug Administration.
Objective:
To review the mechanisms of action, efficacy and safety data, and practical recommendations for ingenol mebutate.
Methods:
The PubMed and clinicaltrials.gov databases were searched in March/April 2012 using the terms PEP005, ingenol mebutate, and ingenol 3-angelate. The abstracts from the Annual Scientific Meeting of the Australian College of Dermatologists (2009–2011) and the Annual Meeting of the American Academy of Dermatology (2009–2012) were also searched.
Results:
Due to its multiple mechanisms of action, ingenol mebutate treatment resulted in short- and long-term efficacy similar to other topical treatments for actinic keratoses in a shorter period of 2 or 3 days. This short therapy would reduce the duration of adverse events. Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate.
Conclusion:
Ingenol mebutate is a convenient, safe, and effective intervention for precancerous and cancerous skin conditions.
Get full access to this article
View all access options for this article.
References
1.
CriscioneVDWeinstockMANaylorMF. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer2009;115:2523–30, doi:10.1002/cncr.24284.
VatveMOrtonneJPBirch-MachinMA. Management of field change in actinic keratosis. Br J Dermatol2007;157Suppl 2:21–4, doi:10.1111/j.1365-2133.2007.08268.x.
KedeiNLundbergDJTothA. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res2004;64:3243–55, doi:10.1158/0008-5472.CAN-03-3403.
11.
OgbourneSMHampsonPLordJM. Proceedings of the First International Conference on PEP005. Anticancer Drugs2007;18:357–62, doi:10.1097/CAD.0b013e3280149ec5.
12.
BoscoRMelloniECeleghiniC. Fine tuning of protein kinase C (PKC) isoforms in cancer: Shortening the distance from the laboratory to the bedside. Mini Rev Med Chem2011;11:185–99, doi:10.2174/138955711795049899.
13.
OgbourneSMSuhrbierAJonesB. Antitumor activity of 3-ingenyl angelate: Plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res2004;64:2833–9, doi:10.1158/0008-5472.CAN-03-2837.
14.
ChallacombeJMSuhrbierAParsonsPG. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol2006;177:8123–32.
15.
CozziSJParsonsPGOgbourneSM. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res2006;66:10083–91, doi:10.1158/0008-5472.CAN-06-0348.
16.
LiLShuklaSLeeA. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res2010;70:4509–19, doi:10.1158/0008-5472.CAN-09-4303.
17.
HampsonPChahalHKhanimF. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood2005;106:1362–8, doi:10.1182/blood-2004-10-4117.
18.
OlsnesAMErsvaerERyningenA. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol2009;145:761–74, doi:10.1111/j.1365-2141.2009.07691.x.
19.
HampsonPWangKMilvertonL. Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis2010;15:946–55, doi:10.1007/s10495-010-0507-7.
20.
LeeWYHampsonPCoulthardL. Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. J Biol Chem2010;285:23889–98, doi:10.1074/jbc.M109.041962.
21.
BenhadjiKASerovaMGhoulA. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer2008;99:1808–15, doi:10.1038/sj.bjc.6604642.
22.
SerovaMGhoulABenhadjiKA. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther2008;7:915–22, doi:10.1158/1535-7163.MCT-07-2060.
23.
GhoulASerovaMAstorgues-XerriL. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res2009;69:4260–9, doi:10.1158/0008-5472.CAN-08-2837.
24.
LeTTGardnerJHoang-LeD. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine2009;27:3053–62, doi:10.1016/j.vac-cine.2009.03.025.
25.
ErsvaerEKittangAOHampsonP. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: A balance between efficacy and toxicity. Toxins (Basel)2010;2:174–94.
26.
RosenRHGuptaAKTyringSK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol2012;66:486–93, doi:10.1016/j.jaad.2010.12.038.
27.
GillespieSKZhangXDHerseyP. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther2004;3:1651–8.
28.
HampsonPKavanaghDSmithE. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother2008;57:1241–51, doi:10.1007/s00262-008-0458-9.
29.
CozziSJOgbourneSMJamesC. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol2012;132:1263–71, doi:10.1038/jid.2011.418.
30.
SillerGGebauerKWelburnP. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa studyAustralas J Dermatol2009;50:16–22, doi:10.1111/j.1440-0960.2008.00497.x.
31.
SpencerJ. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01% and 0.015% when used to treat actinic keratoses on the head. J Am Acad Dermatol2010;62Suppl 3:AB105.
32.
AndersonLSchmiederGJWerschlerWP. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol2009;60:934–43, doi:10.1016/j.jaad.2009.01.008.
33.
RosenR. Ingenol mebutate (PEP005) gel for actinic keratosis: Safety, efficacy, and development status. Australas J Dermatol2009;50Suppl 1:A5.
34.
LamTSKWongOFLeungCHFungHT. A case report of ocular injury by Euphorbia plant sap. Hong Kong J Emerg Med2009;16:267–70.
35.
EkeTAl-HusainySRaynorMK. The spectrum of ocular inflammation caused by Euphorbia plant sap. Arch Ophthalmol2000;118:13–6, doi:10.1001/archopht.118.1.13.
36.
SchmiederG. Multicenter, open-label, dose-area escalation, cohort study to evaluate the safety and tolerability of PEP005 (ingenol mebutate) gel 0.05% applied for two consecutive days to treatment area(s) of up to a total of 100cm2 in patients with actinic keratoses. J Am Acad Dermatol2010;62Suppl 3:AB106.
37.
LebwohlMSwansonNAndersonLL. Ingenol mebutate gel for actinic keratosis. N Engl J Med2012;366:1010–9, doi:10.1056/NEJMoa1111170.
38.
JorizzoJStewartDBuckoA. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-,2-, or 4-week treatment in patients with actinic keratosis. Cutis2002;70:335–9.
39.
WeissJMenterAHeviaO. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis2002;70(2 Suppl):22–9.
40.
LebwohlMDinehartSWhitingD. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol2004;50:714–21, doi:10.1016/j.jaad.2003.12.010.
41.
SzeimiesRMGerritsenMJGuptaG. Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol2004;51:547–55, doi:10.1016/j.jaad.2004.02.022.
42.
KormanNMoyRLingM. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol2005;141:467–73, doi:10.1001/archderm.141.4.467.
43.
HankeCWBeerKRStockflethE. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol2010;62:573–81, doi:10.1016/j.jaad.2009.06.020.
44.
JorizzoJLMarkowitzOLebwohlMG. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol2010;9:1101–8.
45.
SwansonNAbramovitsWBermanB. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol2010;62:582–90, doi:10.1016/j.jaad.2009.07.004.
46.
GebauerKShumackSCowenPS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: A phase II, randomized placebo-controlled trial. Br J Dermatol2009;161:897–903, doi:10.1111/j.1365-2133.2009.09260.x.
47.
RiversJKArletteJShearN. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol2002;146:94–100, doi:10.1046/j.1365-2133.2002.04561.x.
48.
WolfJEJrTaylorJRTschenE. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol2001;40:709–13, doi:10.1046/j.1365-4362.2001.01324.x.
StockflethEMeyerTBenninghoffB. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol2002;138:1498–502, doi:10.1001/archderm.138.11.1498.
51.
OoiTBarnetsonRSZhuangL. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial. Br J Dermatol2006;154:72–8, doi:10.1111/j.1365-2133.2005.06932.x.
52.
GoldLSMelgaardALarssonT. Long-term follow-up studies of ingenol mebutate gel for the treatment of actinic keratosis. J Am Acad Dermatol2012;66 (4Suppl 1):AB154.
53.
HankeCWSwansonNBruceS. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol2011;10:165–70.
54.
StoughDBuckoADVamvakiasG. Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: An 18-month open-label study. Cutis2010;85:267–73.
55.
LawrenceNCoxSECockerellCJ. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol1995;131:176–81, doi:10.1001/archderm.1995.01690140060009.
56.
WitheilerDDLawrenceNCoxSE. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg1997;23:191–6, doi:10.1016/S1076-0512(97)00008-3.
57.
KrawtchenkoNRoewert-HuberJUlrichM. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol2007;157Suppl 2:34–40, doi:10.1111/j.1365-2133.2007.08271.x.
58.
LeePKHarwellWBLovenKH. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg2005;31:659–64, doi:10.1111/j.1524-4725.2005.31608.
59.
JorizzoJDinehartSMathesonR. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol2007;57:265–8, doi:10.1016/j.jaad.2007.01.047.
60.
NelsonCRigelD. Long-term follow up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: One-year evaluation. J Clin Aesthet Dermatol2009;2:20–5.
61.
Kane-MaguireNMoseleyRCozziS-J. Modulation of fibroblast phenotype and extracellular matrix composition by ingenol mebutate may be associated with scar resolution and improved dermal cosmesis. J Am Acad Dermatol2012;66 (4Suppl 1):AB218.
62.
RamsayJRSuhrbierAAylwardJH. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol2011;164:633–6.
63.
NouriKChoudharySMcLeodMP. Treatment of basal cell carcinoma. In: MaibachHGorouhiF, editors. Evidence based dermatology. 2nd ed.Shelton (CT): People's Medical Publishing House-USA; 2011. p. 649–71.
64.
SillerGRosenRFreemanM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: Results of a randomized phase IIa trial. Australas J Dermatol2010;51:99–105, doi:10.1111/j.1440-0960.2010.00626.x.
